POLE and colonic neoplasm: TMB can be used as an important complementary biomarker, such as when combined with MSI, and for identifying other significant gene mutations; it was found, that some MSS colon cancer patients with high TMB had polymerase epsilon (POLE) mutation, and they responded well to immunotherapy (63).